Pfenex (PFNX) Tops Q4 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Pfenex Reports Fourth Quarter and Full Year 2015 Results and Provides Business Update
March 10, 2016 4:05 PM ESTSAN DIEGO, March 10, 2016 /PRNewswire/ --Â Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a business update.
"2015 was a very productive and eventful year for Pfenex," stated Bertrand C. Liang, chief executive officer of Pfenex. "We signed the collaboration agreement for PF582, our biosimilar candidate to Lucentis, with Hospira, now a subsidiary of Pfizer (together, Pfizer) in February 2015,... More
